Landec(LFCR) - 2025 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenues for Q3 2025 were $35.2 million, a decrease of 2% compared to $35.7 million for the same period last year [9] - Gross profit for Q3 2025 was $9.8 million, down from $11.9 million in the prior year, primarily due to a decrease in CDMO gross profit [10] - The company recorded a net loss of $14.8 million or $0.47 per diluted share, compared to net income of $15.6 million or $0.42 per diluted share in the prior year [12] - Adjusted EBITDA for Q3 2025 was $5.7 million, a decrease of $0.7 million compared to $6.4 million in the prior year [12] - For the first nine months of fiscal 2025, revenues were $92.4 million, an increase of 2% compared to $90.4 million for the same period last year [13] Business Line Data and Key Metrics Changes - CDMO revenues decreased by $1.5 million due to the completion of discrete development revenue project life cycles [10] - Hyaluronic acid (HA) manufacturing revenues increased by $1 million due to increased demand from a customer [10] - For the nine months ended February 23, 2025, gross profit was $26.3 million, an increase from $24.6 million in the prior year, driven by increased volumes in HA manufacturing [14] Market Data and Key Metrics Changes - The company signed multiple new agreements with both new and existing customers during the third quarter, indicating strong market engagement [6] - LifeCorps added six new customers during the first nine months of fiscal 2025, including a significant agreement with Nersim Laboratories [25][26] Company Strategy and Development Direction - The company aims to drive a 12% revenue growth category and increase EBITDA margins to over 25% in the coming years [19] - Key growth strategies include maximizing existing customer business, advancing late-stage development programs towards commercialization, and winning new impactful business [20] - The company is focused on reducing operational expenses and enhancing productivity while maintaining high-quality standards [29][30] Management's Comments on Operating Environment and Future Outlook - Management noted that discussions around domestic drug manufacturing have increased among prospective customers, indicating a potential shift in the industry [44] - The company expects to remain cash flow positive from operations in the second half of the fiscal year, with a target of free cash flow neutrality or slight positivity [63] - Management reiterated financial guidance for the fiscal year, expecting revenue to be approximately $126.5 million to $130 million and adjusted EBITDA in the range of $19 to $21 million [17] Other Important Information - The company has made significant improvements in operational efficiencies, including better coordination between supply chain and operations teams [32] - LifeCorps has eliminated numerous consulting relationships in favor of hiring experienced personnel in-house, enhancing operational efficiency [34] Q&A Session Summary Question: Insights on the desire to bring back drug manufacturing in the US - Management noted increased discussions among large multinational pharmaceutical companies regarding the importance of domestic manufacturing, driven by administrative uncertainty [44] Question: Status of the Humanetics contract - The Humanetics contract involves a site transfer from another contract manufacturer, indicating a promising project for LifeCorps [46] Question: Progress on identified opportunities with multinational companies - Management reported positive progress with four large multinationals visiting LifeCorps, indicating a strong sales pipeline [54] Question: Cash flow from operations and capital expenditures - Positive cash flow from operations was approximately $2 million, with capital expenditures around $2 million as well [56][58] Question: Expectations for SG&A expenses moving forward - Management expects SG&A expenses to continue decreasing in the second half of the year, particularly after resolving legacy legal matters [66]